Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06441747
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-04
First Post:
2024-05-29
Brief Title:
Phase II Study of the Combination of Durvalumab MEDI4736 PDL1 Inhibitor and Olaparib PARP Inhibitor in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab BIL-PPP
Sponsor:
Organization:
Australasian Gastro-Intestinal Trials Group